Open AccessTherapy-recalcitrant folliculitis decalvans controlled successfully with adalimumab
Author(s) -
Meshal M Alhameedy,
Adel Alsantali
Publication year - 2019
Publication title -
international journal of trichology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.494
H-Index - 22
eISSN - 0974-9241
pISSN - 0974-7753
DOI - 10.4103/ijt.ijt_92_19
Subject(s) - medicine , dermatology , folliculitis , dapsone , adalimumab , isotretinoin , hydroxychloroquine , trichiasis , scarring alopecia , adverse effect , surgery , immunology , acne , scalp , rheumatoid arthritis , covid-19 , eyelid , infectious disease (medical specialty) , disease
Folliculitis decalvans (FD) is a rare idiopathic primary cicatricial alopecia which leads to permanent destruction of hair follicular stem cell. Staphylococcus aureus as well as autoimmunity has been implicated in the pathogenesis. Treatment options include topical antiseptics, topical and systemic corticosteroids, systemic antibiotics, isotretinoin, dapsone, hydroxychloroquine, and immunomodulators. We present the therapy-recalcitrant case of FD which is controlled successfully by subcutaneous injections of Adalimumab (Humira ® ) with no serious adverse events throughout the treatment.